News First-in-class BMS drug raises lung fibrosis hopes Bristol-Myers Squibb has proof-of-concept data for an experimental drug for fibrotic diseases that could open up a new avenue for treatment.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.